Table 1.
Demographic Data of the Participants and the Clinical Characteristics at Baseline and Follow-Up of the Subjects at Clinical High Risk (CHR) for Psychosis
| HC | CHR-Ra | CHR-NRb | Statistical Analysisc | |||||
|---|---|---|---|---|---|---|---|---|
| (N = 47) | (N = 17) | (N = 31) | ||||||
| Mean | SD | Mean | SD | Mean | SD | χ2 or F or t | P | |
| Baseline characteristics | ||||||||
| Sex (male/female) | 29/18 | 11/6 | 24/7 | 2.166 | .339 | |||
| Handedness (right/left) | 46/1 | 17/0 | 28/3 | 3.550 | .169 | |||
| Age (years) | 24.6 | 5.3 | 19.8 | 3.6 | 19.5 | 3.4 | 14.696 | <.001** |
| IQ | 115.3 | 13.4 | 107.6 | 12.0 | 106.9 | 12.5 | 4.758 | .011* |
| Education (years) | 14.5 | 1.8 | 12.1 | 1.4 | 12.1 | 1.7 | 23.133 | <.001* |
| DUPP (months) | NA | 22.4 | 23.0 | 21.0 | 17.0 | 0.237 | .814 | |
| SOPS | ||||||||
| Positive symptoms | NA | 7.8 | 3.5 | 8.3 | 5.5 | −0.335 | .739 | |
| Negative symptoms | NA | 15.6 | 5.9 | 14.9 | 6.5 | 0.376 | .709 | |
| Disorganization | NA | 4.2 | 1.9 | 4.7 | 2.8 | −0.665 | .509 | |
| General symptoms | NA | 7.8 | 3.9 | 7.3 | 4.3 | 0.400 | .691 | |
| GAF | NA | 48.5 | 8.4 | 41.9 | 23.2 | 1.422 | .163 | |
| Follow-up characteristics | ||||||||
| Follow-up duration (days) | NA | 1141.7 | 612.5 | 1059.8 | 511.7 | 0.494 | .624 | |
| Antipsychotics dosed | NA | 1.9 | 2.3 | 3.6 | 3.4 | −2.080 | .043* | |
| Change in | ||||||||
| SOPS positive symptomse | NA | 4.7 | 3.3 | 4.1 | 8.3 | 0.378 | .707 | |
| GAFf | NA | 20.4 | 9.5 | 4.4 | 12.4 | 4.586 | <.001** | |
| Number of follow-up (months)g | ||||||||
| 12 months | NA | 14 (29.2) | 21 (43.8) | 1.187 | .276 | |||
| 18 months | NA | 12 (25.0) | 13 (27.1) | 3.612 | .057 | |||
| 24 months | NA | 10 (20.8) | 18 (37.5) | 0.003 | .959 | |||
| 36 months | NA | 7 (14.6) | 13 (27.1) | 0.003 | .959 | |||
| 48 months | NA | 5 (10.4) | 6 (12.5) | 0.629 | .428 | |||
| 60 months | NA | 4 (8.3) | 4 (8.3) | 0.893 | .345 | |||
| 72 months | NA | 2 (4.2) | 2 (4.2) | 0.406 | .524 | |||
| Use of medicationh | ||||||||
| Antipsychotics | NA | 14 (82.3) | 29 (93.5) | 1.475 | .225 | |||
| Antidepressants | NA | 12 (70.6) | 21 (67.7) | 0.041 | .839 | |||
| Mood stabilizers | NA | 11 (64.7) | 22 (71.0) | 0.200 | .654 | |||
| Anxiolytics | NA | 4 (23.5) | 13 (41.9) | 1.626 | .202 | |||
Note: HC, healthy control; SD, standard deviation; IQ, intelligence quotient; DUPP, duration of untreated prodromal psychosis; SOPS, Scale of Prodromal Symptoms; GAF, Global Assessment of Functioning; NA, not applicable.
aRemitted at last follow-up point.
bDid not remit at last follow-up point.
cAnalysis of variance, independent t-test or Welch’s t-test if the variances were not equal; χ2 analysis or Fisher’s exact test for categorical data.
dMean daily olanzapine equivalent dose prescribed during the follow-up period.
eCalculated by subtracting scores at last follow-up point from scores at baseline.
fCalculated by subtracting scores at baseline from scores at last follow-up point.
gNumber (percentage) of subjects who were followed-up at that time point.
hNumber (percentage) of subjects who were prescribed each medication during the follow-up period.
*The mean difference is significant at the .05 level.
**The mean difference is significant at the .005 level.